Navigation Links
bioTheranostics Announces Commercial Agreement With Lab21 to Market THEROS CancerTYPE ID(R) Molecular Cancer Classifier in United Kingdom, Ireland and Middle East Countries
Date:10/6/2009

rove patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agro-food, pharmaceutical and cosmetic products. bioMerieux is listed on the NYSE Euronext Paris market (Code: BIM - Code ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

About Lab21 Limited

Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting blood bank screening, medical diagnostics and drug discovery. Its customers include international healthcare providers, pharmaceutical and biotechnology companies. The service division has a growing test portfolio providing companion diagnostics and high technology molecular assays for the growing integration of personalized medicine into healthcare. These services are currently in infectious diseases, oncology and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease. The product division of the Company manufactures immunodiagnostic kits and reagents that are distributed into 110 international countries and is focused on infectious diseases for the blood-banking market. More information is available at www.lab21.com.

    Contact:  Media Relations
    Michele Parisi
    925/429-1850
    mparisi@biocommnetwork.com

    Investor Relations
    David Dai
    317/331-6185
    david.dai@biotheranostics.com

SOURCE bioTheranostics


'/>"/>
SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. One Source Industries Announces Promotion
2. The Symphony Guild Announces Artist Lineup for 2009 Event
3. Hanger Orthopedic Group, Inc. Announces Third Quarter 2009 Earnings Release Conference Call
4. China-Biotics, Inc. Announces Closing of Public Offering of Common Stock
5. Trapeze Networks Announces Trapeze Medical, Bringing Medical-Grade Mobility to Healthcare Market
6. Vertical Measures Announces its Version of Healthcare Reform by Giving Away 5K in Internet Marketing Services
7. Arcxis Biotechnologies Announces Release of First Commercial Product for Molecular Analysis
8. The Pennsylvania Breast Cancer Coalition Announces Request for Applications for Income Tax Check-Off Research Grants
9. NIDDK announces availability of more current kidney disease data
10. APWU Health Plan Announces New Benefits and Premiums for 2010
11. Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera(TM) for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Park Avenue Dental, a leading Florida-based dental ... top graduate of the University of Detroit School of ... website through an ultra-informative blog focused on dental tips ... the blog page is chock full of topics that ... concentrating on important dental care tips including ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Ticket Down ... tickets in NYC. In just a week, the U.S. ... King Tennis Center. The event was originally founded in 1881 and ... Rafael Nadal was forced to withdrawal from the event because of ... women’s tournament and will return to New York City with hopes ...
(Date:8/20/2014)... Line: Less than 42 percent of women underwent ... the factors associated with foregoing reconstruction included being ... older. , Author: Monica Morrow, M.D., of the ... colleagues. , Background: The Women,s Health and Cancer ... breast reconstruction following a mastectomy. Still, most women ...
(Date:8/20/2014)... (HealthDay News) -- Pigs, hearts transplanted into baboons survived ... long as previously achieved, researchers report. The work ... animal organs to shorten transplant waiting lists. In ... into baboons, abdomens. The genetic engineering and new methods ... enabled the hearts to survive for more than a ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 (HealthDay ... an option, but a new study shows that only about ... reasons women didn,t undergo reconstruction was that they felt it ... were focused on their cancer treatment," said lead researcher Dr. ... Cancer Center, in New York City. Also common was ...
Breaking Medicine News(10 mins):Health News:Park Avenue Dental Provides Dental Care Tips for World Wide Community on New Website Blog 2Health News:Park Avenue Dental Provides Dental Care Tips for World Wide Community on New Website Blog 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3
... of ColdFusion Web content management solutions, today announced ... all company records, having grown an average of ... company’s average deal size increased by more than ... profitable since its inception in 1993. The company’s ...
... Edwards and breast cancer ... tough times, FERNDALE, Mich., Nov. 13 On Wednesday, ... inspiration in,life,s challenges to the Troy Hilton, at 5500 Crooks ... Parent Magazine are proud to,present this unique opportunity, entitled "An ...
... Nov. 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), ... for cardiovascular disease, today announced financial results,for the three ... operating loss for the three months ended September 30, ... $5.5 million, or $0.35 per,share, for the same period ...
... of suppressing immune response , , THURSDAY, Nov. 13 (HealthDay ... responses offers promise in efforts to develop treatments for ... a painful, inflammatory form of arthritis -- occurs when ... Foxp3 plays an important role in immune system regulation. ...
... with higher levels of phosphate in the blood are ... the coronary arteriesa key indicator of atherosclerosis and future ... 2009 issue of the Journal of the American ... represent a previously unidentified and modifiable cardiovascular risk factor, ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... will be held November 18-19, 2008 at The New,York ... Tuesday, November 18th at 11:00 am,ET., HMS Holdings ... in,coordination of benefits and program integrity services for government,healthcare ...
Cached Medicine News:Health News: PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate 2Health News: PaperThin Experiences Record Growth : Grows Revenues, Expands Channel, and Maintains 95%+ Subscription Renewal Rate 3Health News:Elizabeth Edwards Reschedules Metro Detroit Appearance 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:New Therapy Could Transform Arthritis Treatment 2Health News:High-normal phosphate levels linked to early atherosclerosis 2
(Date:8/20/2014)... Torrance Memorial Medical Center announced today ... from Covidien to provide a simple, safe and ... The acute care ventilator is designed to help ... ventilation, and help clinicians move patients off mechanical ... ventilation are often sedated to ease agitation and ...
(Date:8/20/2014)... New York , August 20, 2014 ... a new market report titled "Monochloroacetic Acid (MCA) Market ... Applications - Global Industry Analysis, Size, Share, Growth, Trends ... market was valued at USD 817.1 million in 2013 ... 2020, growing at a CAGR of 3.6% during the ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 2012.  For the first quarter of 2012, the Company reported ... compared with a net income of $2.9 million, or $0.05 ... $3.8 million change in operating results is primarily due to ...
... Janssen Research & Development, LLC, (Janssen), announced today ... to the U.S. Food and Drug Administration (FDA) seeking ... an oral anticoagulant, to treat patients with deep vein ... recurrent venous thromboembolism (VTE). These submissions are ...
Cached Medicine Technology:Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8
... This type of anchor is generally utilized when ... directly into the bone. Unlike other anchors that ... anchor does not have that limitation. The only ... is a mallet. The 4.4mm Stainless Steel Anchor ...
... Yasushi Nakao, M.D., Smith & Nephew ... flexor,tendon release for fingers and thumbs ... approach is designed to decrease patient ... of releasing the A1 pulley under ...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: